D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s target price points to a potential upside of 286.06% from the stock’s previous close.

A number of other research firms also recently issued reports on OMER. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research report on Friday. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research note on Friday, January 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Trading Up 2.5 %

Shares of OMER stock traded up $0.23 during trading hours on Friday, hitting $9.33. 375,215 shares of the company were exchanged, compared to its average volume of 527,428. Omeros has a 52 week low of $2.61 and a 52 week high of $13.60. The business has a 50 day moving average of $8.70 and a two-hundred day moving average of $7.28. The company has a market capitalization of $540.38 million, a PE ratio of -4.03 and a beta of 2.03.

Hedge Funds Weigh In On Omeros

A number of hedge funds have recently bought and sold shares of OMER. Truvestments Capital LLC increased its stake in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 1,972 shares during the period. Quantbot Technologies LP bought a new stake in Omeros in the fourth quarter valued at $46,000. BNP Paribas Financial Markets raised its holdings in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares during the period. Finally, Picton Mahoney Asset Management raised its holdings in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the period. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.